Zymeworks Q2 2026: Net Loss Widens to $45M; Cash at $179M; Zanidatamab PDUFA Aug 25
ZYME has more than doubled off its 52-week low of $11.51.
Summary
Zymeworks posted a $45M quarterly loss as collaboration revenue dried up, but cash remains strong at $322.5M. All eyes are on the August 25 PDUFA for zanidatamab, which could unlock a $250M milestone and transform the royalty stream.
Key Events · Earnings and Guidance · ZYME
-
Q2 Net Loss of $45.0M
Revenue fell to $4.6M from $48.7M a year ago, primarily due to the absence of large one-time milestone payments. Operating expenses declined 5% to $46.8M, but interest expense of $6.6M from the Royalty Pharma loan pushed the bottom line deeper into the red.
-
Cash and Liquidity
Cash, equivalents, and marketable securities totaled $322.5M at quarter-end, bolstered by the $250M royalty monetization in March. The company also carries a $252.6M liability related to the sale of future royalties.
-
Zanidatamab PDUFA Date August 25, 2026
The FDA is reviewing the sBLA for zanidatamab in first-line HER2+ GEA with a target action date of August 25. Approval would trigger a $250M milestone payment from Jazz and BeOne and is expected to significantly increase royalty revenue.
-
Aggressive Share Repurchases Continue
The company repurchased 2,008,243 shares for $51.9M in Q2 under the new $125M 2026 Repurchase Program. Since August 2024, cumulative repurchases total $213.6M, reducing the share count by over 10 million shares.
Analysis · ZYME · Life Sciences
A $45.0M net loss in Q2 2026 reflects a steep decline in collaboration revenue and higher interest expense tied to the Royalty Pharma loan. While cash and marketable securities stand at $322.5M, the balance sheet now includes a $252.6M liability from the royalty monetization. The August 25 PDUFA date for zanidatamab in first-line GEA looms as a pivotal binary event — approval would unlock a $250M milestone payment and materially lift royalty revenue. The filing also reveals a new employment agreement for the General Counsel and continued aggressive buybacks, with $51.9M repurchased in Q2 under the new $125M program.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.1% of the 1612 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZYME was trading at $23.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $11.51 to $29.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.